Does the media refer more to CLPT or DRTS?

In the previous week, ClearPoint Neuro had 2 more articles in the media than Alpha Tau Medical. MarketBeat recorded 5 mentions for ClearPoint Neuro and 3 mentions for Alpha Tau Medical. Alpha Tau Medical's average media sentiment score of 0.05 beat ClearPoint Neuro's score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Tau Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TNDM or CLPT?

In the previous week, Tandem Diabetes Care had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Tandem Diabetes Care and 5 mentions for ClearPoint Neuro. Tandem Diabetes Care's average media sentiment score of 1.24 beat ClearPoint Neuro's score of 0.00 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CLPT or BVS?

In the previous week, ClearPoint Neuro had 3 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for ClearPoint Neuro and 2 mentions for Bioventus. ClearPoint Neuro's average media sentiment score of 0.00 equaled Bioventus'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CLPT or STAA?

In the previous week, STAAR Surgical had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for STAAR Surgical and 5 mentions for ClearPoint Neuro. STAAR Surgical's average media sentiment score of 0.29 beat ClearPoint Neuro's score of 0.00 indicating that STAAR Surgical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral STAAR Surgical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

ClearPoint Neuro (CLPT) Competitors

$10.48 -0.01 (-0.10%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.68 +0.20 (+1.91%)

As of 10/9/2026 07:30 PM Eastern

Compare

CLPT vs. DRTS, TNDM, BVS, STAA, and AORT

Should you buy ClearPoint Neuro stock or one of its competitors? ClearPoint Neuro's main competitors and comparable companies include Alpha Tau Medical (DRTS), Tandem Diabetes Care (TNDM), Bioventus (BVS), STAAR Surgical (STAA), and Artivion (AORT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ClearPoint Neuro compare to Alpha Tau Medical?

ClearPoint Neuro (NASDAQ:CLPT) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Alpha Tau Medical has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -81.76%. Alpha Tau Medical's return on equity of -138.12% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Alpha Tau Medical	N/A	-138.12%	-81.68%

ClearPoint Neuro currently has a consensus price target of $25.67, suggesting a potential upside of 144.91%. Alpha Tau Medical has a consensus price target of $15.40, suggesting a potential upside of 6.87%. Given ClearPoint Neuro's higher probable upside, research analysts clearly believe ClearPoint Neuro is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, ClearPoint Neuro had 2 more articles in the media than Alpha Tau Medical. MarketBeat recorded 5 mentions for ClearPoint Neuro and 3 mentions for Alpha Tau Medical. Alpha Tau Medical's average media sentiment score of 0.05 beat ClearPoint Neuro's score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Tau Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ClearPoint Neuro has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

ClearPoint Neuro has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	8.65	-$25.54M	-$1.18	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$1.04	N/A

Summary

ClearPoint Neuro beats Alpha Tau Medical on 8 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Tandem Diabetes Care had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Tandem Diabetes Care and 5 mentions for ClearPoint Neuro. Tandem Diabetes Care's average media sentiment score of 1.24 beat ClearPoint Neuro's score of 0.00 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tandem Diabetes Care has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Tandem Diabetes Care currently has a consensus price target of $27.18, indicating a potential upside of 68.74%. ClearPoint Neuro has a consensus price target of $25.67, indicating a potential upside of 144.91%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.43
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Tandem Diabetes Care has a net margin of -6.08% compared to ClearPoint Neuro's net margin of -81.76%. Tandem Diabetes Care's return on equity of -45.97% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

30.1% of ClearPoint Neuro shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ClearPoint Neuro has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.10	-$204.71M	-$0.93	N/A
ClearPoint Neuro	$36.97M	8.65	-$25.54M	-$1.18	N/A

Summary

Tandem Diabetes Care beats ClearPoint Neuro on 11 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to Bioventus?

ClearPoint Neuro (NASDAQ:CLPT) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by company insiders. Comparatively, 33.5% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ClearPoint Neuro had 3 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for ClearPoint Neuro and 2 mentions for Bioventus. ClearPoint Neuro's average media sentiment score of 0.00 equaled Bioventus'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventus has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	8.65	-$25.54M	-$1.18	N/A
Bioventus	$568.09M	1.93	$22.73M	$0.77	16.96

ClearPoint Neuro presently has a consensus target price of $25.67, suggesting a potential upside of 144.91%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 28.64%. Given ClearPoint Neuro's higher probable upside, equities analysts clearly believe ClearPoint Neuro is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bioventus	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bioventus has a net margin of 9.36% compared to ClearPoint Neuro's net margin of -81.76%. Bioventus' return on equity of 28.08% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Bioventus	9.36%	28.08%	9.82%

Summary

Bioventus beats ClearPoint Neuro on 11 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to STAAR Surgical?

ClearPoint Neuro (NASDAQ:CLPT) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

STAAR Surgical has a net margin of 1.13% compared to ClearPoint Neuro's net margin of -81.76%. STAAR Surgical's return on equity of 9.05% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
STAAR Surgical	1.13%	9.05%	6.99%

In the previous week, STAAR Surgical had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for STAAR Surgical and 5 mentions for ClearPoint Neuro. STAAR Surgical's average media sentiment score of 0.29 beat ClearPoint Neuro's score of 0.00 indicating that STAAR Surgical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
STAAR Surgical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 39.9% of STAAR Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ClearPoint Neuro has higher earnings, but lower revenue than STAAR Surgical. ClearPoint Neuro is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	8.65	-$25.54M	-$1.18	N/A
STAAR Surgical	$239.44M	4.54	-$80.45M	$0.07	309.57

ClearPoint Neuro currently has a consensus price target of $25.67, suggesting a potential upside of 144.91%. STAAR Surgical has a consensus price target of $28.45, suggesting a potential upside of 31.31%. Given ClearPoint Neuro's stronger consensus rating and higher probable upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
STAAR Surgical	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

STAAR Surgical beats ClearPoint Neuro on 11 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to Artivion?

Artivion (NYSE:AORT) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Artivion currently has a consensus target price of $44.83, suggesting a potential upside of 110.58%. ClearPoint Neuro has a consensus target price of $25.67, suggesting a potential upside of 144.91%. Given ClearPoint Neuro's higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Artivion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Artivion has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

In the previous week, ClearPoint Neuro had 5 more articles in the media than Artivion. MarketBeat recorded 5 mentions for ClearPoint Neuro and 0 mentions for Artivion. Artivion's average media sentiment score of 0.00 equaled ClearPoint Neuro'saverage media sentiment score.

Company	Overall Sentiment
Artivion	Neutral
ClearPoint Neuro	Neutral

86.4% of Artivion shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 6.3% of Artivion shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Artivion has higher revenue and earnings than ClearPoint Neuro. Artivion is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.35	$9.77M	-$0.07	N/A
ClearPoint Neuro	$36.97M	8.65	-$25.54M	-$1.18	N/A

Artivion has a net margin of -0.67% compared to ClearPoint Neuro's net margin of -81.76%. Artivion's return on equity of 6.07% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

Summary

Artivion beats ClearPoint Neuro on 9 of the 15 factors compared between the two stocks.

Get ClearPoint Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLPT vs. The Competition

Export

Metric	ClearPoint Neuro	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$319.99M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-8.88	25.57	274.15	26.16
Price / Sales	8.65	83.25	635.98	113.06
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	10.59	5.93	11.21	6.34
Net Income	-$25.54M	$146.18M	$3.50B	$381.90M
7 Day Performance	-3.85%	-0.38%	-0.90%	-1.41%
1 Month Performance	-22.26%	-2.02%	-4.44%	-3.48%
1 Year Performance	-59.86%	5.08%	6.96%	1.16%

ClearPoint Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLPT ClearPoint Neuro	1.5541 of 5 stars	$10.48 -0.1%	$25.67 +144.9%	-63.8%	$319.99M	$36.97M	N/A	172	News Coverage
DRTS Alpha Tau Medical	1.7829 of 5 stars	$14.57 -2.2%	$15.40 +5.7%	+272.4%	$1.31B	N/A	N/A	121
TNDM Tandem Diabetes Care	2.8484 of 5 stars	$16.38 -0.9%	$29.13 +77.9%	+8.7%	$1.14B	$1.01B	N/A	2,500	Analyst Forecast Gap Down
BVS Bioventus	3.2742 of 5 stars	$13.21 -2.3%	$16.80 +27.2%	+98.2%	$1.12B	$568.09M	17.29	950	News Coverage Analyst Upgrade
STAA STAAR Surgical	4.0568 of 5 stars	$22.20 -1.6%	$28.45 +28.2%	-17.2%	$1.12B	$339.59M	318.39	957	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLPT) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Competitors

CLPT vs. DRTS, TNDM, BVS, STAA, and AORT

How does ClearPoint Neuro compare to Alpha Tau Medical?

Summary

How does ClearPoint Neuro compare to Tandem Diabetes Care?

Summary

How does ClearPoint Neuro compare to Bioventus?

Summary

How does ClearPoint Neuro compare to STAAR Surgical?

Summary

How does ClearPoint Neuro compare to Artivion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Competitors

CLPT vs. DRTS, TNDM, BVS, STAA, and AORT

How does ClearPoint Neuro compare to Alpha Tau Medical?

Is CLPT or DRTS more profitable?

Do analysts rate CLPT or DRTS?

Does the media refer more to CLPT or DRTS?

Do insiders & institutionals have more ownership in CLPT or DRTS?

Which has more risk & volatility, CLPT or DRTS?

Which has stronger valuation and earnings, CLPT or DRTS?

Summary

How does ClearPoint Neuro compare to Tandem Diabetes Care?

Does the media prefer TNDM or CLPT?

Which has more volatility & risk, TNDM or CLPT?

Do analysts rate TNDM or CLPT?

Is TNDM or CLPT more profitable?

Do insiders & institutionals believe in TNDM or CLPT?

Which has higher valuation & earnings, TNDM or CLPT?

Summary

How does ClearPoint Neuro compare to Bioventus?

Which has more risk & volatility, CLPT or BVS?

Do insiders & institutionals hold more shares of CLPT or BVS?

Does the media prefer CLPT or BVS?

Which has preferable earnings and valuation, CLPT or BVS?

Do analysts prefer CLPT or BVS?

Is CLPT or BVS more profitable?

Summary

How does ClearPoint Neuro compare to STAAR Surgical?

Which has more volatility & risk, CLPT or STAA?

Is CLPT or STAA more profitable?

Does the media favor CLPT or STAA?

Do insiders and institutionals hold more shares of CLPT or STAA?

Which has stronger earnings and valuation, CLPT or STAA?

Do analysts recommend CLPT or STAA?

Summary

How does ClearPoint Neuro compare to Artivion?

Do analysts recommend AORT or CLPT?

Which has more volatility and risk, AORT or CLPT?

Does the media prefer AORT or CLPT?

Do insiders & institutionals hold more shares of AORT or CLPT?

Which has better earnings and valuation, AORT or CLPT?

Is AORT or CLPT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools